{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:49:46Z","timestamp":1790743786846,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> Rituximab is frequently used off-label for the treatment of frequent-relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS), but the relapse rate remained high and the dosing regimen varied widely. The objective of this study was to characterize rituximab pharmacokinetics (PK) in pediatric patients with FRNS\/SDNS, and to investigate the differences in rituximab PK between patients with FRNS\/SDNS and other disease populations.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Fourteen pediatric patients received rituximab for FRNS\/SDNS treatment were enrolled in a prospective, open-label, single-center PK study. A population PK model of rituximab was developed and validated, and PK parameters were derived for quantitative evaluation.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A two-compartment PK model best described the data. Body surface area was the most significant covariate for both central clearance (CL) and apparent central volume of distribution (V<jats:sub>1<\/jats:sub>). Patients with FRNS\/SDNS exhibited a clinically relevant increase in rituximab CL compared to patient population with non-Hodgkin\u2019s lymphoma (NHL).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This pilot study indicated that higher doses or more frequent regimens of rituximab may be required for optimal therapeutic effects in patients with FRNS\/SDNS. Further clinical studies with more patients are warranted to confirm this result.<\/jats:p>","DOI":"10.3389\/fphar.2021.725665","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T02:32:45Z","timestamp":1630722765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Yewei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-dependent Nephrotic Syndrome: A Randomized Clinical Trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1472-8206.2009.00714.x","article-title":"Pharmacokinetics of Rituximab Associated with CHOP Chemotherapy in B-Cell Non-hodgkin Lymphoma","volume":"23","author":"Blasco","year":"2009","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-018-3524-9","article-title":"Comparative Assessment of Pharmacokinetics, and Pharmacodynamics between RTXM83\u2122, a Rituximab Biosimilar, and Rituximab in Diffuse Large B-Cell Lymphoma Patients: a Population PK Model Approach","volume":"81","author":"Candelaria","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00467-015-3120-8","article-title":"Pharmacokinetics of Rituximab in a Pediatric Patient with Therapy-Resistant Nephrotic Syndrome","volume":"30","author":"Counsilman","year":"2015","journal-title":"Pediatr. Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03891.x","article-title":"Interpreting Population Pharmacokinetic-Pharmacodynamic Analyses - a Clinical Viewpoint","volume":"71","author":"Duffull","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1177\/0091270003253624","article-title":"Model Appropriateness and Population Pharmacokinetic Modeling","volume":"43","author":"Ette","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/1060028018803587","article-title":"Rituximab Exhibits Altered Pharmacokinetics in Patients with Membranous Nephropathy","volume":"53","author":"Fogueri","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","article-title":"Lessons for the Clinic from Rituximab Pharmacokinetics and Pharmacodynamics","volume":"5","author":"Golay","year":"2013","journal-title":"MAbs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00280-016-3083-x","article-title":"Population Pharmacokinetics of Reditux\u2122, a Biosimilar Rituximab, in Diffuse Large B-Cell Lymphoma","volume":"78","author":"Gota","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","article-title":"Effect of Different Rituximab Regimens on B Cell Depletion and Time to Relapse in Children with Steroid-dependent Nephrotic Syndrome","volume":"34","author":"Hogan","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"B11","volume-title":"The Visual Predictive Check-Superiority to Standard Diagnostic (Rorschach) plotsAbstract of the Annual Meeting of the Population Approach Group in Europe","author":"Holford","year":"2005"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for Childhood-Onset, Complicated, Frequently Relapsing Nephrotic Syndrome or Steroid-dependent Nephrotic Syndrome: a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/ki.1978.23","article-title":"Nephrotic Syndrome in Children: Prediction of Histopathology from Clinical and Laboratory Characteristics at Time of Diagnosis. A Report of the International Study of Kidney Disease in Children","volume":"13","year":"1978","journal-title":"Kidney Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/s0022-3476(81)80760-3","article-title":"The Primary Nephrotic Syndrome in Children. Identification of Patients with Minimal Change Nephrotic Syndrome from Initial Response to Prednisone. A Report of the International Study of Kidney Disease in Children","volume":"98","year":"1981","journal-title":"J. Pediatr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","article-title":"Single Dose of Rituximab for Refractory Steroid-dependent Nephrotic Syndrome in Children","volume":"24","author":"Kamei","year":"2009","journal-title":"Pediatr. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2165\/11201110-000000000-00000","article-title":"Rituximab: a Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","article-title":"Long-term Follow-Up after Rituximab for Steroid-dependent Idiopathic Nephrotic Syndrome","volume":"27","author":"Kemper","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0091270011430506","article-title":"Population Pharmacokinetics of Rituximab in Patients with Chronic Lymphocytic Leukemia","volume":"52","author":"Li","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/bcp.13270","article-title":"Antigenic burden and Serum IgG Concentrations Influence Rituximab Pharmacokinetics in Rheumatoid Arthritis Patients","volume":"83","author":"Lioger","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00467-018-4172-3","article-title":"Low-dose Rituximab Is No Less Effective for Nephrotic Syndrome Measured by 12-month Outcome","volume":"34","author":"Maxted","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development-Part 2: Introduction to Pharmacokinetic Modeling Methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The Role of Sex and Weight on Rituximab Clearance and Serum Elimination Half-Life in Elderly Patients with DLBCL","volume":"119","author":"M\u00fcller","year":"2012","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0091270005277075","article-title":"Population Pharmacokinetics of Rituximab (Anti-CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients during a Phase II Clinical Trial","volume":"45","author":"Ng","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3345\/kjp.2011.54.8.322","article-title":"Complications of Nephrotic Syndrome","volume":"54","author":"Park","year":"2011","journal-title":"Korean J. Pediatr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/bcp.12098","article-title":"Population Pharmacokinetics of Rituximab with or without Plasmapheresis in Kidney Patients with Antibody-Mediated Disease","volume":"76","author":"Puisset","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term Effects of Rituximab in Children with Steroid- and Calcineurin-dependent Nephrotic Syndrome: a Randomized Controlled Trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","article-title":"Rituximab Is a Safe and Effective Long-Term Treatment for Children with Steroid and Calcineurin Inhibitor-dependent Idiopathic Nephrotic Syndrome","volume":"84","author":"Ravani","year":"2013","journal-title":"Kidney Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in Children with Steroid-dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","article-title":"Pharmacokinetic Behavior of Rituximab: a Study of Different Schedules of Administration for Heterogeneous Clinical Settings","volume":"27","author":"Regazzi","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/bcp.13271","article-title":"Population Pharmacokinetics of Rituximab in Patients with Diffuse Large B-Cell Lymphoma and Association with Clinical Outcome","volume":"83","author":"Rozman","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/s0022-3476(88)80570-5","article-title":"Predicting the Response to Cytotoxic Therapy for Childhood Nephrotic Syndrome: Superiority of Response to Corticosteroid Therapy over Histopathologic Patterns","volume":"113","author":"Schulman","year":"1988","journal-title":"J. Pediatr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New Equations to Estimate GFR in Children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B33","volume-title":"Clinical Commissioning Policy: Rituximab for the Treatment of Relapsing Steroid Sensitive Nephrotic Syndrome","year":"2015"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/bcp.13991","article-title":"Nonlinear Pharmacokinetics of Rituximab in Non-hodgkin Lymphomas: A Pilot Study","volume":"85","author":"Ternant","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","article-title":"Rituximab Exposure Is Influenced by Baseline Metabolic Tumor Volume and Predicts Outcome of DLBCL Patients: a Lymphoma Study Association Report","volume":"129","author":"Tout","year":"2017","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40262-016-0470-8","article-title":"Influence of FCGR3A-158V\/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group","volume":"56","author":"Tout","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1177\/0091270011422812","article-title":"Clarification on Precision Criteria to Derive Sample Size when Designing Pediatric Pharmacokinetic Studies","volume":"52","author":"Wang","year":"2012","journal-title":"J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.725665\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T02:32:49Z","timestamp":1630722769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.725665\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":37,"alternative-id":["10.3389\/fphar.2021.725665"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.725665","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"article-number":"725665"}}